title: Haplotype association between GABAA receptor gamma2 subunit gene (GABRG2) and methamphetamine use disorder.
abstract: Psychostimulant use disorder and schizophrenia have a substantial genetic basis. Evidence from human and animal studies on the involvement of the gamma-aminobutyric acid (GABA) system in methamphetamine (METH) use disorder and schizophrenia is mounting. As we tested for the association of the human GABA(A) receptor gamma 2 subunit gene (GABRG2) with each diagnostic group, we used a case-control design with a set of 178 subjects with METH use disorder, 288 schizophrenics and 288 controls. First, we screened 96 controls and identified six SNPs in GABRG2, three of whom we newly reported. Next, we selected two SNPs, 315C>T and 1128+99C>A, as representatives of the linkage disequilibrium blocks for further case-control association analysis. Although no associations were found in either allelic or genotypic frequencies, we detected a haplotypic association in GABRG2 with METH use disorder, but not with schizophrenia. This finding partly replicates a recent case-control study of GABRG2 in METH use disorder, and thus indicates that GABRG2 may be one of the susceptibility genes of METH use disorder.
authors.affiliation: Department of Psychiatry, Fujita Health University School of Medicine, Aichi, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Nishiyama
authors.forename: M
authors.initials: M
authors.lastname: Ikeda
authors.forename: N
authors.initials: N
authors.lastname: Iwata
authors.forename: T
authors.initials: T
authors.lastname: Suzuki
authors.forename: T
authors.initials: T
authors.lastname: Kitajima
authors.forename: Y
authors.initials: Y
authors.lastname: Yamanouchi
authors.forename: Y
authors.initials: Y
authors.lastname: Sekine
authors.forename: M
authors.initials: M
authors.lastname: Iyo
authors.forename: M
authors.initials: M
authors.lastname: Harano
authors.forename: T
authors.initials: T
authors.lastname: Komiyama
authors.forename: M
authors.initials: M
authors.lastname: Yamada
authors.forename: I
authors.initials: I
authors.lastname: Sora
authors.forename: H
authors.initials: H
authors.lastname: Ujike
authors.forename: T
authors.initials: T
authors.lastname: Inada
authors.forename: T
authors.initials: T
authors.lastname: Furukawa
authors.forename: N
authors.initials: N
authors.lastname: Ozaki
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000465:Algorithms; D000483:Alleles; D019969:Amphetamine-Related Disorders / Q000235:genetics*; D016022:Case-Control Studies; D000697:Central Nervous System Stimulants; D005260:Female; D005787:Gene Frequency; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006239:Haplotypes; D006801:Humans; D015810:Linkage Disequilibrium / Q000235:genetics; D008297:Male; D008694:Methamphetamine; D008875:Middle Aged; D011110:Polymorphism, Genetic / Q000235:genetics; D020641:Polymorphism, Single Nucleotide / Q000235:genetics; D011569:Psychiatric Status Rating Scales; D011963:Receptors, GABA-A; D018080:Receptors, GABA-B / Q000235:genetics*; D012559:Schizophrenia / Q000235:genetics
chemical_list: D000697:Central Nervous System Stimulants; C106350:GABRR2 protein, human; D011963:Receptors, GABA-A; D018080:Receptors, GABA-B; D008694:Methamphetamine